You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Not Available
Identification
NameRapacuronium
Accession NumberDB04834
TypeSmall Molecule
GroupsWithdrawn
DescriptionRapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RaplonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Rapacuronium bromide
156137-99-4
Thumb
  • InChI Key: LVQTUXZKLGXYIU-GWSNJHLMSA-M
  • Monoisotopic Mass: 676.381471097
  • Average Mass: 677.795
DBSALT000337
Categories
UNIIGG1LBM463S
CAS number465499-11-0
WeightAverage: 597.904
Monoisotopic: 597.462584872
Chemical FormulaC37H61N2O4
InChI KeyHTIKWNNIPGXLGM-YLINKJIISA-N
InChI
InChI=1S/C37H61N2O4/c1-6-20-39(21-12-9-13-22-39)32-24-30-28-15-14-27-23-33(42-26(3)40)31(38-18-10-8-11-19-38)25-37(27,5)29(28)16-17-36(30,4)35(32)43-34(41)7-2/h6,27-33,35H,1,7-25H2,2-5H3/q+1/t27-,28+,29-,30-,31-,32-,33-,35-,36-,37-/m0/s1
IUPAC Name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5-(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)-14-(propanoyloxy)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-13-yl]-1-(prop-2-en-1-yl)piperidin-1-ium
SMILES
[H][C@@]12C[C@@H]([[email protected]](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[[email protected]](OC(C)=O)[[email protected]](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1
Pharmacology
IndicationUsed in anaesthesia, to aid and enable endotracheal intubation.
Structured Indications Not Available
PharmacodynamicsRapacuronium is a rapidly acting, non-depolarizing neuromuscular blocker.
Mechanism of action
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingVariable. Plasma protein binding of rapacuronium was studied in vitro for human plasma by equilibrium dialysis. The protein binding was variable and ranged between 50% and 88%, which was at least partly due to hydrolysis of rapacuronium bromide to its 3-hydroxy metabolite. The specific plasma protein to which rapacuronium binds is unknown. Plasma protein binding of the 3-hydroxy metabolite was not determined.
Metabolism

Hydrolyzed to active metabolites (Cytochrome P450 system is not involved).

Route of eliminationNot Available
Half life141 minutes (mean)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may decrease the neuromuscular blocking activities of Rapacuronium.Experimental
16-BromoepiandrosteroneRapacuronium may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneRapacuronium may increase the adverse neuromuscular activities of 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneRapacuronium may increase the adverse neuromuscular activities of 4-Androstenedione.Experimental, Illicit
5-androstenedioneRapacuronium may increase the adverse neuromuscular activities of 5-androstenedione.Experimental, Illicit
AcetyldigitoxinRapacuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AclarubicinAclarubicin may increase the respiratory depressant activities of Rapacuronium.Investigational
AlclometasoneRapacuronium may increase the adverse neuromuscular activities of Alclometasone.Approved
AldosteroneRapacuronium may increase the adverse neuromuscular activities of Aldosterone.Experimental
AmbenoniumAmbenonium may decrease the neuromuscular blocking activities of Rapacuronium.Approved
AmcinonideRapacuronium may increase the adverse neuromuscular activities of Amcinonide.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Rapacuronium.Approved, Vet Approved
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
AmrinoneAmrinone may increase the neuromuscular blocking activities of Rapacuronium.Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational
AnecortaveRapacuronium may increase the adverse neuromuscular activities of Anecortave.Investigational
annamycinannamycin may increase the respiratory depressant activities of Rapacuronium.Investigational
AnvirzelRapacuronium may increase the arrhythmogenic activities of Anvirzel.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Rapacuronium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Rapacuronium.Approved
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
AzimilideAzimilide may increase the neuromuscular blocking activities of Rapacuronium.Investigational
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
BeclomethasoneRapacuronium may increase the adverse neuromuscular activities of Beclomethasone.Investigational
Beclomethasone dipropionateRapacuronium may increase the adverse neuromuscular activities of Beclomethasone dipropionate.Approved, Investigational
BenidipineBenidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
BepridilBepridil may increase the neuromuscular blocking activities of Rapacuronium.Approved, Withdrawn
BetamethasoneRapacuronium may increase the adverse neuromuscular activities of Betamethasone.Approved, Vet Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
Botulinum Toxin Type BRapacuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BudesonideRapacuronium may increase the adverse neuromuscular activities of Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Rapacuronium.Approved
CaiCai may increase the neuromuscular blocking activities of Rapacuronium.Investigational
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Rapacuronium.Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
CiclesonideRapacuronium may increase the adverse neuromuscular activities of Ciclesonide.Approved, Investigational
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Rapacuronium.Approved
ClevidipineClevidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
ClindamycinClindamycin may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
ClobetasolRapacuronium may increase the adverse neuromuscular activities of Clobetasol.Investigational
Clobetasol propionateRapacuronium may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
ClocortoloneRapacuronium may increase the adverse neuromuscular activities of Clocortolone.Approved
ColistimethateColistimethate may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
Cortisone acetateRapacuronium may increase the adverse neuromuscular activities of Cortisone acetate.Approved
CoumaphosCoumaphos may decrease the neuromuscular blocking activities of Rapacuronium.Vet Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Vet Approved
DarodipineDarodipine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Rapacuronium.Approved
DecamethoniumDecamethonium may decrease the neuromuscular blocking activities of Rapacuronium.Approved
dehydroepiandrosterone sulfateRapacuronium may increase the adverse neuromuscular activities of dehydroepiandrosterone sulfate.Investigational
DemecariumDemecarium may decrease the neuromuscular blocking activities of Rapacuronium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Rapacuronium.Approved
DesfluraneDesflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved
DeslanosideRapacuronium may increase the arrhythmogenic activities of Deslanoside.Approved
DesoximetasoneRapacuronium may increase the adverse neuromuscular activities of Desoximetasone.Approved
Desoxycorticosterone acetateRapacuronium may increase the adverse neuromuscular activities of Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateRapacuronium may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneRapacuronium may increase the adverse neuromuscular activities of Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateRapacuronium may increase the adverse neuromuscular activities of Dexamethasone isonicotinate.Vet Approved
DichlorvosDichlorvos may decrease the neuromuscular blocking activities of Rapacuronium.Vet Approved
DiflorasoneRapacuronium may increase the adverse neuromuscular activities of Diflorasone.Approved
DifluocortoloneRapacuronium may increase the adverse neuromuscular activities of Difluocortolone.Approved
DifluprednateRapacuronium may increase the adverse neuromuscular activities of Difluprednate.Approved
DigitoxinRapacuronium may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinRapacuronium may increase the arrhythmogenic activities of Digoxin.Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Rapacuronium.Vet Approved
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Rapacuronium.Approved
DonepezilDonepezil may decrease the neuromuscular blocking activities of Rapacuronium.Approved
DotarizineDotarizine may increase the neuromuscular blocking activities of Rapacuronium.Investigational
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational, Vet Approved
EchothiophateEchothiophate may decrease the neuromuscular blocking activities of Rapacuronium.Approved
EdrophoniumEdrophonium may decrease the neuromuscular blocking activities of Rapacuronium.Approved
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
EnfluraneEnflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
EperisoneEperisone may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
EpirubicinEpirubicin may increase the respiratory depressant activities of Rapacuronium.Approved
EquileninRapacuronium may increase the adverse neuromuscular activities of Equilenin.Experimental
EquilinRapacuronium may increase the adverse neuromuscular activities of Equilin.Approved
EstroneRapacuronium may increase the adverse neuromuscular activities of Estrone.Approved
Estrone sulfateRapacuronium may increase the adverse neuromuscular activities of Estrone sulfate.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Rapacuronium.Approved
FelodipineFelodipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
FendilineFendiline may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
FenthionFenthion may decrease the neuromuscular blocking activities of Rapacuronium.Vet Approved
fluasteroneRapacuronium may increase the adverse neuromuscular activities of fluasterone.Investigational
FludrocortisoneRapacuronium may increase the adverse neuromuscular activities of Fludrocortisone.Approved
FlumethasoneRapacuronium may increase the adverse neuromuscular activities of Flumethasone.Approved, Vet Approved
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Rapacuronium.Approved
FlunisolideRapacuronium may increase the adverse neuromuscular activities of Flunisolide.Approved, Investigational
Fluocinolone AcetonideRapacuronium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideRapacuronium may increase the adverse neuromuscular activities of Fluocinonide.Approved, Investigational
FluocortoloneRapacuronium may increase the adverse neuromuscular activities of Fluocortolone.Approved, Withdrawn
FluorometholoneRapacuronium may increase the adverse neuromuscular activities of Fluorometholone.Approved
FluprednideneRapacuronium may increase the adverse neuromuscular activities of Fluprednidene.Approved, Withdrawn
FluprednisoloneRapacuronium may increase the adverse neuromuscular activities of Fluprednisolone.Approved
FlurandrenolideRapacuronium may increase the adverse neuromuscular activities of Flurandrenolide.Approved
Fluticasone furoateRapacuronium may increase the adverse neuromuscular activities of Fluticasone furoate.Approved
Fluticasone PropionateRapacuronium may increase the adverse neuromuscular activities of Fluticasone Propionate.Approved
FormestaneRapacuronium may increase the adverse neuromuscular activities of Formestane.Approved, Investigational, Withdrawn
FosphenytoinFosphenytoin may decrease the neuromuscular blocking activities of Rapacuronium.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Rapacuronium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
GabapentinGabapentin may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
GalantamineGalantamine may decrease the neuromuscular blocking activities of Rapacuronium.Approved
Gallamine TriethiodideGallamine Triethiodide may decrease the neuromuscular blocking activities of Rapacuronium.Approved
GallopamilGallopamil may increase the neuromuscular blocking activities of Rapacuronium.Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Rapacuronium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Rapacuronium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Rapacuronium.Experimental
Ginkgo bilobaGinkgo biloba may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Nutraceutical
HalothaneHalothane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
HE3286Rapacuronium may increase the adverse neuromuscular activities of HE3286.Investigational
Huperzine AHuperzine A may decrease the neuromuscular blocking activities of Rapacuronium.Investigational
HydrocortisoneRapacuronium may increase the adverse neuromuscular activities of Hydrocortisone.Approved, Vet Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Rapacuronium.Vet Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Rapacuronium.Approved
INNO-206INNO-206 may increase the respiratory depressant activities of Rapacuronium.Investigational
IsofluraneIsoflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
IsoflurophateIsoflurophate may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Withdrawn
IsradipineIsradipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
IstaroximeRapacuronium may increase the adverse neuromuscular activities of Istaroxime.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Rapacuronium.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Rapacuronium.Approved
LacidipineLacidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
LithiumLithium may increase the neuromuscular blocking activities of Rapacuronium.Approved
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Rapacuronium.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Rapacuronium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Rapacuronium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
MalathionMalathion may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
ManidipineManidipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
ME-609Rapacuronium may increase the adverse neuromuscular activities of ME-609.Investigational
MedrysoneRapacuronium may increase the adverse neuromuscular activities of Medrysone.Approved
MefloquineMefloquine may decrease the neuromuscular blocking activities of Rapacuronium.Approved
MelengestrolRapacuronium may increase the adverse neuromuscular activities of Melengestrol.Vet Approved
MemantineMemantine may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
Methanesulfonyl FluorideMethanesulfonyl Fluoride may decrease the neuromuscular blocking activities of Rapacuronium.Investigational
MethoxyfluraneMethoxyflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
MethylprednisoloneRapacuronium may increase the adverse neuromuscular activities of Methylprednisolone.Approved, Vet Approved
MetrizamideMetrizamide may increase the respiratory depressant activities of Rapacuronium.Approved
MibefradilMibefradil may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
MinaprineMinaprine may decrease the neuromuscular blocking activities of Rapacuronium.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
MometasoneRapacuronium may increase the adverse neuromuscular activities of Mometasone.Approved, Vet Approved
NaftopidilNaftopidil may increase the neuromuscular blocking activities of Rapacuronium.Investigational
NCX 1022Rapacuronium may increase the adverse neuromuscular activities of NCX 1022.Investigational
NeamineNeamine may increase the respiratory depressant activities of Rapacuronium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Rapacuronium.Approved, Vet Approved
NeostigmineNeostigmine may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Rapacuronium.Approved
NicardipineNicardipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
NifedipineNifedipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
NiludipineNiludipine may increase the neuromuscular blocking activities of Rapacuronium.Experimental
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
NimesulideNimesulide may increase the neuromuscular blocking activities of Rapacuronium.Approved, Withdrawn
NimodipineNimodipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Rapacuronium.Approved
Nitrous oxideNitrous oxide may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
Oleoyl estroneRapacuronium may increase the adverse neuromuscular activities of Oleoyl estrone.Investigational
OuabainRapacuronium may increase the arrhythmogenic activities of Ouabain.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
ParamethasoneRapacuronium may increase the adverse neuromuscular activities of Paramethasone.Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational
PerhexilinePerhexiline may increase the neuromuscular blocking activities of Rapacuronium.Approved
PhenytoinPhenytoin may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
PhysostigminePhysostigmine may decrease the neuromuscular blocking activities of Rapacuronium.Approved
PinaveriumPinaverium may increase the neuromuscular blocking activities of Rapacuronium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Rapacuronium.Investigational
PiretanidePiretanide may decrease the neuromuscular blocking activities of Rapacuronium.Experimental
PlicamycinPlicamycin may increase the respiratory depressant activities of Rapacuronium.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
PrasteroneRapacuronium may increase the adverse neuromuscular activities of Prasterone.Approved, Nutraceutical
PrednicarbateRapacuronium may increase the adverse neuromuscular activities of Prednicarbate.Approved
PrednisoloneRapacuronium may increase the adverse neuromuscular activities of Prednisolone.Approved, Vet Approved
PrednisoneRapacuronium may increase the adverse neuromuscular activities of Prednisone.Approved, Vet Approved
PregabalinPregabalin may increase the neuromuscular blocking activities of Rapacuronium.Approved, Illicit, Investigational
PregnenoloneRapacuronium may increase the adverse neuromuscular activities of Pregnenolone.Experimental
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
ProcainamideProcainamide may increase the neuromuscular blocking activities of Rapacuronium.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Rapacuronium.Experimental
PyridostigminePyridostigmine may decrease the neuromuscular blocking activities of Rapacuronium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Rapacuronium.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Rapacuronium.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Rapacuronium.Approved
RimexoloneRapacuronium may increase the adverse neuromuscular activities of Rimexolone.Approved
RisedronateRisedronate may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
RivastigmineRivastigmine may decrease the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
SevofluraneSevoflurane may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
SisomicinSisomicin may increase the respiratory depressant activities of Rapacuronium.Investigational
SP1049CSP1049C may increase the respiratory depressant activities of Rapacuronium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Rapacuronium.Approved, Vet Approved
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Rapacuronium.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Rapacuronium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Rapacuronium.Approved
TacrineTacrine may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
TetracyclineTetracycline may increase the neuromuscular blocking activities of Rapacuronium.Approved, Vet Approved
TixocortolRapacuronium may increase the adverse neuromuscular activities of Tixocortol.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Rapacuronium.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Rapacuronium.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Rapacuronium.Approved
TranilastTranilast may increase the neuromuscular blocking activities of Rapacuronium.Approved, Investigational
TriamcinoloneRapacuronium may increase the adverse neuromuscular activities of Triamcinolone.Approved, Vet Approved
TrichlorfonTrichlorfon may decrease the neuromuscular blocking activities of Rapacuronium.Vet Approved
TubocurarineTubocurarine may decrease the neuromuscular blocking activities of Rapacuronium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Rapacuronium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Rapacuronium.Approved
VerapamilVerapamil may increase the neuromuscular blocking activities of Rapacuronium.Approved
VinpocetineVinpocetine may increase the neuromuscular blocking activities of Rapacuronium.Investigational
XylometazolineXylometazoline may increase the neuromuscular blocking activities of Rapacuronium.Approved
ZiconotideZiconotide may increase the neuromuscular blocking activities of Rapacuronium.Approved
ZorubicinZorubicin may increase the respiratory depressant activities of Rapacuronium.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5993
Blood Brain Barrier+0.8937
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.8064
P-glycoprotein inhibitor IInhibitor0.8735
P-glycoprotein inhibitor IIInhibitor0.908
Renal organic cation transporterNon-inhibitor0.7446
CYP450 2C9 substrateNon-substrate0.85
CYP450 2D6 substrateNon-substrate0.7966
CYP450 3A4 substrateSubstrate0.7018
CYP450 1A2 substrateNon-inhibitor0.7843
CYP450 2C9 inhibitorNon-inhibitor0.851
CYP450 2D6 inhibitorNon-inhibitor0.8561
CYP450 2C19 inhibitorNon-inhibitor0.7692
CYP450 3A4 inhibitorNon-inhibitor0.6044
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7403
Ames testNon AMES toxic0.6904
CarcinogenicityNon-carcinogens0.8664
BiodegradationNot ready biodegradable0.9886
Rat acute toxicity2.6637 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8796
hERG inhibition (predictor II)Non-inhibitor0.7349
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5418226 No1993-04-142013-04-14Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility4.64e-06 mg/mLALOGPS
logP3.79ALOGPS
logP2.32ChemAxon
logS-8.1ALOGPS
pKa (Strongest Basic)9.65ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area55.84 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity183.1 m3·mol-1ChemAxon
Polarizability72.25 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Androstane-skeleton
  • Dicarboxylic acid or derivatives
  • Piperidine
  • Tetraalkylammonium salt
  • Quaternary ammonium salt
  • Acetate salt
  • Amino acid or derivatives
  • Carboxylic acid ester
  • Tertiary amine
  • Tertiary aliphatic amine
  • Azacycle
  • Carboxylic acid derivative
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organooxygen compound
  • Organonitrogen compound
  • Organic oxygen compound
  • Amine
  • Carbonyl group
  • Organic nitrogen compound
  • Organic cation
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available
Comments
comments powered by Disqus
Drug created on September 11, 2007 15:43 / Updated on August 17, 2016 12:24